As of 11:30 AM on the 6th, Access Bio is trading at 13,000 KRW, up 5.69% from the previous day. This represents a 286.33% increase compared to July 9. Access Bio is known as a specialized manufacturer of in vitro diagnostic products, including malaria diagnostic kits.
Over the past 5 days, individual investors have net purchased 443,283 shares, while foreign investors and institutions have net sold 115,764 shares and 318,609 shares, respectively.
On August 3, Access Bio made headlines in the market with the news of its COVID-19 diagnostic kit receiving FDA emergency approval, causing the stock to hit the upper price limit again.
※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
